On May 20, 2020, Rapid Micro Biosystems announced a $120 million financing round, led by equity investment from VC firms in Asia, EU and U.S. including: lead investor Ally Bridge (Hong Kong), Endeavour Vision (Geneva), U.S. investors Bain Capital Life Sciences and Longitude Capital.

The company planned to use the financing to expand access to its Growth Direct platform that has been adopted by more than half of the top 20 biopharmaceutical companies at manufacturing plants around the globe.

The company’s Growth Direct platform automates the majority of standard microbial QC tests, replacing the time- and labor-intensive manual QC processes and delivering results in half the time. Fully automated microbial contaminant testing can be performed with minimal human handling and remote system monitoring and data reporting capabilities to ensure manufacturing continuity at a time when QC labs must remain fully operational, despite reduced staff due to COVID-19 restrictions.

The ability to compress timelines and ensure sterility is particularly suited to bioprocessing for state-of the-art manufacturing and for complex new therapeutic modalities, as well as ensuring the delivery of safe medicines for patients.

Rapid Micro Biosystems has its global headquarters and manufacturing facility in Lowell, Massachusetts.